Plant closure hurts Orchid's earnings; J&J comes up with more Doxil;

> Indian API-maker Orchid Chemicals & Pharmaceuticals reported dismal results in its last quarter, in part because a plant in India was closed after pollution concerns. Story

> Johnson & Johnson ($JNJ), which has restricted Doxil treatment to current cancer patients because of manufacturing problems at the Ben Venue Laboratories plant where it was made, now has a limited supply that will be made available for up to 2,000 new patients. News

> Contract manufacturer Angel Biotechnology Holdings ($ABH) has paid £200,000 ($320,470) for a 6,500-square-foot biomaterial and collagen manufacturing plant in Glasgow, U.K., to make purified GMP medical-grade collagen. Release

> With a new plant in China, Danish biotech group Novozymes is now producing hyaluronic acid for pharmaceutical manufacturers. More

> The International Conference on Harmonisation (ICH) has sent its Q11 guidelines on API manufacturing to regulators in the U.S., EU and Japan in an effort to standardize applications. Item

> API-maker Flamma Italy has bought a plant near Milan that will allow it to handle industrial production of triphosgene and ammonia gas. Article

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.